Nivalis Therapeutics, Inc. (extinct)

Nivalis Therapeutics, Inc. (extinct)

Nivalis Therapeutics, Inc. (extinct)

Overview
Date Founded

2008

Headquarters

3122 Sterling Circle,Suite 200,Boulder, CO 80301

Type of Company

Private

Employees (Worldwide)

11 - 50

Industries

Pharmaceuticals
Hospitals & Patient Services
Biotechnology

Company Description

Nivalis Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in discovery, development, and commercialization of product for patients with cystic fibrosis. Its product includes N91115, a small molecule that addresses a defect in the cystic fibrosis transmembrane conductance regulator. The company was founded in 2008 and is headquartered in Boulder, CO.

Contact Data
Trying to get in touch with decision makers at Nivalis Therapeutics, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

President Chief Operating Officer

Paths to Nivalis Therapeutics, Inc.
Potential Connections via
Relationship Science
You
Nivalis Therapeutics, Inc.
Recent Transactions
Details Hidden

Nivalis Therapeutics, Inc. issued Common Stock

Details Hidden

Nivalis Therapeutics, Inc. raised money in a private placement transaction

Transaction Advisors
Escrow Agent

Advised onNivalis Therapeutics, Inc. issued Common Stock

Underwriter

Advised onNivalis Therapeutics, Inc. issued Common Stock

Underwriter

Advised onNivalis Therapeutics, Inc. issued Common Stock

Advisors & Consultants
Publicist

Professional at Elixir Health Public Relations

Publicist

Senior Vice President at Trout Capital LLC

Practice Lead at The W2O Group

Investors
Details Hidden

Wellington Management Co. LLP (Private Equity) focuses in companies located in US. The firm invests in consumer discretionary, technology, financial services, biotech, and health care. They provide capital for growth and later stage capital requirement.

Details Hidden

Deerfield Management Co. focuses on investments in growth stocks across the healthcare sector. They target companies with sound fundamentals, long-term earnings growth potential and the potential to capitalize on market trends. Deerfield's approach is based on extensive fundamental research into healthcare sector assets and investment opportunities. They invest mainly in US companies or companies that issue securities available in US public markets. Although this is their focus, there is no geographic limitation on investments and Deerfield may invest outside the US when situations warrant. Their funds generally pursue one of 3 strategies: Large-Cap, Special Situations and Private Design.Deerfield's Large-Cap strategy invests mainly in debt and equity securities, including exchange traded derivative securities, of publicly-traded companies in the healthcare sector. The strategy seeks capital appreciation through a combination of security selection based on fundamental analysis, diversification through investments in stock, debt and derivatives and a mix of long and short positions.The firm's Special Situations strategy emphasizes investments in publicly traded healthcare companies with smaller market-caps. At least 90% of investments must in healthcare companies, and essentially all investments are healthcare related. Investments include equity, debt, royalties or other assets, some of which may have limited liquidity. The strategy makes both long and short investments and may utilize leverage.Deerfield's Private Design strategy invests in public and private healthcare companies using privately created instruments, structures and transactions. This may include, but is not limited to, joint ventures, project financing, contracting for revenue streams, purchasing products/services outright (including intellectual property), participating in LBOs, restructurings and outright buyouts, and developing/participating in the development and sale of therapeutics, medical devices and healthcare products/services.

Details Hidden

Deerfield Capital Management (DCM) is a global fixed-income investment manager that manages client assets, including bank loans and other corporate debt, residential MBS, government securities and ABS. The firm manages structured products including CLOs that invest mainly in bank loans and CDOs that invest mainly in ABS and corporate bonds.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Nivalis Therapeutics, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Nivalis Therapeutics, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Nivalis Therapeutics, Inc..